A Single-center, Randomized, Active-controlled and Evaluator-blind Investigator-initiated Trial to Evaluate and Compare the Efficacy and Safety of CT-guided Needle Guidance Using Stereotaxic Unit, Navigation Versus Conventional Biopsy Technique for the Patients Scheduled to Undergo Percutaneous Pulmonary Nodule Biopsy

Hyung Jin Won0 sites106 target enrollmentNovember 2017

ConditionsPercutaneous Pulmonary Nodule Biopsy

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Percutaneous Pulmonary Nodule Biopsy
Sponsor: Hyung Jin Won
Enrollment: 106
Primary Endpoint: Needle guide accuracy(mm)
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study was to compare the safety and efficacy of CT-guided needle guidance using stereotaxic unit, navigation versus conventional biopsy technique for the patients scheduled to undergo percutaneous pulmonary nodule biopsy.

Registry

clinicaltrials.gov

Start Date

November 2017

End Date

June 2019

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hyung Jin Won

Responsible Party

Sponsor Investigator

Principal Investigator

Hyung Jin Won

Professor

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

•Patient with localized lesions such as pulmonary nodules on chest x-ray, CT or PET CT
•Histopathologic examination is necessary if lung lesion is unknown
•Histologic findings affect the disease stage or treatment plan
•If the investigator decides to perform a percutaneous lung biopsy because the biopsy or diagnosis through the bronchoscopy is not possible or has low risk-benefit
•Patient who have consented to contraception during the period of clinical trial participation (one month after the procedure)
•Patient who voluntarily agree to participate in this clinical trial and are willing to comply with the protocol

Exclusion Criteria

•Patient with pulmonary function insufficiency
•Patient who has difficulty in self-breathing (e.g, breathing through oxygen breathing apparatus)
•Patient with Uncontrolled coagulation disorders (INR \> 1.3 or Blood platelet count \< 50,000/µl)
•Patient with allergy to CT contrast agent
•Patient under 19 years old or over 80 years old
•Pregnant or lactating
•Patient with uncontrollable systemic disease (e.g, uncontrolled hypertension, uncontrolled cardiovascular disease, etc.)
•Patient who currently participating or has participated in other clinical trials within 30 days of the screening date
•If it is judged inappropriate to participate in this clinical trial under the judgment of the investigator